Autotelic Bio announced that it has signed an agreement with Clinigen Group, a global pharmaceutical company based in the UK, for the clinical trials of Autotelic Bio's ATB-301, an immuno-therapeutic dual-function anticancer pipeline currently under development. Through this Agreement, Clinigen will supply their interleukin-2, with the global brand name Proleukin (Aldesleukin) for the clinical studies to be conducted by Autotelic Bio. The detailed deal structure of this agreement has not been disclosed. 

Due to the agreement with Clinigen Group, Autotelic Bio will proceed seamlessly with the Korean Phase 1b clinical trial of ATB-301. ATB-301, an immuno-target dual-action anticancer therapeutic, combines the functions of TGF-β2 inhibition and T-cell activation. It is a therapeutic that can weaken defensive mechanism of cancer cell by suppressing TGF-β2 and simultaneously strengthen T cell's functions to attack cancer cells, resulting in a synergistic anticancer effect.